Table 4.
Baseline and procedural characteristics and 30-day outcomes of patients undergoing TTV replacement.
| Orthotopic valves | Heterotopic valves | |||||
|---|---|---|---|---|---|---|
| Navigate | Evoque | LuX-Valve | Sapien XT | Tricento | ||
| Hahn et al. (37) | Fam et al. (38) | Webb et al. (39) | Lu et al. (40) | Dreger et al. (41) | Schaefer et al. (42) | |
| N of patients | 30 | 25 | 132 | 12 | 14 | 27 |
| Age | 75 ± 10 | 76 ± 3 | 79 ± 7 | 69 (66–74) | 75 ± 8 | 73 ± 10 |
| STS-PROM score, % | NA | 9.1 ± 2.3 | 5.3 ± 4.3 | NA | NA | NA |
| Euroscore II | 11.1% (7.1–14.1%) | 7.7 ± 2.2 | 7.4 ± 5.39 | NA | NA | NA |
| Functional TR | NA | 19 (76) | 93 (70.5) | NA | NA | NA |
| TR severity | ||||||
| - None-/Moderate | 2 (6.6) | 4 (16) | 13 (12) | 0 | 0 (0) | NA |
| - ≥Severe | 28 (92.4) | 21 (84) | 119 (88) | 12 (100) | 14 (100) | |
| Procedural outcomes | ||||||
| Procedural success | 26 (87) | 23 (92) | 128 (96) | 12 (0) | 14 (100) | 30 (96.1) |
| Conversion to open surgery | 2 (6.6) | 0 | NA | NA | 4 (28) | NA |
| Device embolization or malposition | 0 | 0 | NA | 0 (0) | 4 (28) | 1 (3) |
| 30-day outcomes | ||||||
| Mortality | 3 (10) | 0 | 4 (3.2) | 1 (8) | 3 (21) | NA |
| Stroke | 1 (3.3) | 0 | 0 (0) | 0 | NA | NA |
| Major or life-threatening bleeding | 10 (30) | 3(12) | 2 (2) | 1 (8) | 3 (21) | NA |
| TR severity | ||||||
| - None-Moderate | 18 (76) | 23 (92) | NA | 11 (92) | NA | NA |
| - ≥Severe | 6 (24) | 2 (8) | NA | 1 (8) | NA | NA |
Continuous values are expressed as mean ± SD, mean (range) and median (interquartile range) as reported by authors. Categorical values are expressed as n (%).
TR, tricuspid regurgitation.